[1] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版).肝脏, 2015,20: 915-932.
[2] World Health Organization. Global tuberculosis report 2015. http: //www.who.int/tb/publications/global_report/en/.
[3] Wasserman S,Meintjes G.The diagnosis, management and prevention of HIV-associated tuberculosis. S Afr Med J,2014,104: 886-893.
[4] Sumantri S, Djoerban Z. Clinical Manifestations and Antiretroviral Management of HIV/AIDS Patients with Tuberculosis Co-infection in Kramat 128 Hospital. Acta Med Indones-Indones J Intern Med,2008,40: 117-123.
[5] Onyebujoh PC,Ribeiro I,Whalen CC. Treatment Options for HIV-Associated Tuberculosis. J Infect Dis, 2007, 196(Suppl 1): S35-45.
[6] Cohen K,Meintjes G. Management of individuals requiring ART and TB treatment. Curr Opin HIV AIDS, 2010,5: 61-69.
[7] See comment in PubMed Commons beloMatthews PC,Geretti AM,Goulder PJ,et al. Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. J Clin Virol, 2014, 61: 20-33.
[8] Huang SM, Cai WP, Hu FY, et al. Epidemiological and clinical characteristics of hepatitis B virus in HIV-infected patients in Guangdong, China. Int J STD AIDS, 2015,18. pii: 0956462415600570.
[9] Soriano V1, Labarga P, de Mendoza C, et al. Emerging challenges in managing hepatitis B in HIV patients. Curr HIV/AIDS Rep, 2015,12: 344-352.
[10] Xie J, Han Y, Qiu ZF,et al. Prevalence of hepatitis B and C viruses in HIV-positive patients in China: a cross-sectional study. J International AIDS Society, 2016,19: 20659.
[11] 李慕才,胡伟朋,鸟耶春平.肺结核合并乙型肝炎患者肝损害的合理治疗探讨.中国医药指南, 2012,10: 66-67.
[12] Bushnell G, Stennis NL, Drobnik AM,et al. Characteristics and TB treatment outcomes in TB patients with viral hepatitis, New York City, 2000-2010. Epidemiol Infect, 2015,143: 1972-1981.
[13] Blal CA, Passos SR, Horn C,et al. High prevalence of hepatitis B virus infection among tuberculosis patients with and without HIV in Rio de Janeiro, Brazil. Eur J Clin Microbiol Infect Dis,2005,24: 41-43.
[14] Kuniholm MH, Mark J, Aladashvili M, et al. Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients. Int J Infect Dis, 2008,12: 51-56.
[15] Nooredinvand HA,Connell DW,Asgheddi M, et al. Viral hepatitis prevalence in patients with active and latent tuberculosis. World J Gastroenterol, 2015,21: 8920-8926.
[16] Sirinak C, Kittikraisak W, Pinjeesekikul D, et al. Viral hepatitis and HIV-associated tuberculosis: risk factors and TB treatment outcomes in Thailand. BMC Public Health, 2008,8: 245.
[17] 吴伟文.肺结核合并乙肝病毒感染的治疗. 浙江医学,2001,23: 429-430.
[18] 徐吉英, 王国斌, 王国杰,等. 涂阳肺结核病人乙型肝炎病毒感染流行病学研究. 现代预防医学,2005,32: 918-919.
[19] 魏成翠,刘阿玲,贾琳,等.沈阳地区肺结核病患者乙肝病毒感染情况调查.临床肺科杂志, 2009,14: 691-692.
[20] 李飞跃,申辉,杨华林,等.涂阳肺结核合并乙型肝炎流行病学分析.实用预防医学,2010,17: 280-281.
[21] 刘丰平.结核患者乙肝病毒感染分析. 实用预防医学, 2011, 18: 1663-1664.
[22] 许光辉, 蒙是升, 陈华,等.合并乙肝病毒感染的肺结核患者发生药物性肝炎的临床分析. 现代诊断与治疗,2013,24: 2888-2890.
[23] 叶小霞. 82例初治与复治肺结核患者HBsAg携带率调查. 河南医学研究,2014,23: 147-149.
[24] 朱小宁.浅析合并乙肝病毒感染的肺结核患者的流行病学特征. 当代医学论丛,2015,13: 259-260.
[25] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南. 肝脏,2015,20: 750-762.
[26] 中华医学会结核病学分会.抗结核药物所致药物性肝损伤诊断与处理专家建议.中华结核与呼吸杂志,2013,36: 732-736.
[27] Kin WS, Lee SS, Lee CM,et al. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infect Dis, 2016,16: 50.
[28] 郭虹,李环,李淑芬,等.抗结核药物所致肝损害的发生机制及影响因素. 北京大学学报:自然科学版,2006,7: 159-161.
[29] Kappus MR,Sterling RK. Extrahepatic manifestations of acute hepatitis B virus infection. Gastroenterol Hepatol (NY), 2013,9: 123-126.
[30] Arora S1, Prakash TV2, Carey RA2, Hansdak SG2. Poncet's disease: unusual presentation of a common disease. Lancet, 2016,387(10018): 617-618.
[31] 郑积才. 16例结核风湿症临床分析. 临床肺科杂志,2006, 12: 337.
[32] 宗成光. 结核风湿症25例临床分析. 中国实用医药,2013,8: 52-53.
[33] 于淑霞,高合斌. 慢性乙型病毒性肝炎的肝外表现.临床消化病杂志,1998,10: 125-126.
[34] Rostey RR,Souto FJ.Observational descriptive study of cutaneous manifestations in patients from Mato Grosso with viral chronic hepatitis. An Bras Dermatol, 2015,90: 828-835.
[35] Ba kova TA, Lopatkina TN.A variety of extrahepatic manifestations of chronic viral hepatitis B and C: basic treatment principles. Ter Arkh, 2013,85: 106-110.
[36] Hwang JP,Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol, 2014,11: 209-19.
[37] 中华医学会结核病学分会. 临床诊疗指南:结核病学分册. 2015修订电子版. 北京:人民卫生出版社,2016.
[38] 胡良安, 傅玉, 罗永艾,等. 结核性胸膜炎抗结核中发生类赫氏反应的危险因素. 第三军医大学学报, 2013, 35: 57-60.
[39] 张琳,任俊杰,黄戈,等. 免疫抑制剂相关肺结核的临床特点及X线表现. 临床放射学杂志, 2007,26: 679-682.
[40] Critchley JA,young F,OrtonL,et al. Corticosteroids for prevention of mortality in people with tuberculosis :a systematic review and meta-analysis. lancet Infect Dis, 2013, 13: 223-237.
[41] Perrillo RP. Hepatitis B reactivation from immunosuppressive drug therapy: A global menace: Editor's comment for February issue of clinical liver disease. Clinical Liver Disease,2015, 5: 39-42.
[42] Sabbatani S, Manfredi R, Marinacci G, et al. Reactivation of severe, acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis. Scand J Infect Dis,2006, 38: 205-208.
[43] Farah R, Awad J. The association of interferon with the development of pulmonary tuberculosis. Int J Clin Pharmacol Ther,2007,45: 598-600.
[44] Rodríguez-Medina B, Blanes M, Vinaixa C, et al. Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir. Ann Hepatol,2013,12: 974-978.
[45] Babudieri S, Soddu A, Murino M,et al. Tuberculosis screening before anti-hepatitis C virus therapy in prisons. Emerg Infect Dis,2012,18: 689-691.
[46] Telesca C, Angelico M, Piccolo P, et al. Interferon-alpha treatment of hepatitis D induces tuberculosis exacerbation in an immigrant. J Infect,2007,54: 223-226.
[47] Lin SY, Chen TC, Lu PL,et al. Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan. BMC Infectious Diseases, 2014, 14: 1-8. |
